𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Efficacy of budipine and placebo in untreated patients with Parkinson’s disease

✍ Scribed by T. Müller; W. Kuhn; H. Przuntek

Publisher
Springer
Year
2004
Tongue
English
Weight
142 KB
Volume
112
Category
Article
ISSN
1435-1463

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Adjuvant treatment of Parkinson's diseas
Adjuvant treatment of Parkinson's disease with budipine: a double-blind trial versus placebo
✍ Kurt Jellinger; Harald Bliesath 📂 Article 📅 1987 🏛 Springer 🌐 English ⚖ 307 KB

Budipine, a new 4,4-diphenylpiperidine derivative, and placebo were administered three times daily to 31 patients with Parkinson's disease over a period of 12 weeks. All patients in the two treatment groups received levodopa (plus benserazide) at an optimum and constant dose for at least 2 months be

Exercise improves efficacy of levodopa i
Exercise improves efficacy of levodopa in patients with Parkinson's disease
✍ Siegfried Muhlack; Jacub Welnic; Dirk Woitalla; Thomas Müller 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB 👁 1 views

## Abstract The objective was to investigate the impact of exercise on absorption and efficacy of levodopa (LD) in patients with Parkinson‘s disease (PD). A soluble, immediate release LD formulation was given followed by exercise near the aerobic limit on one day to PD patients, who underwent the s

Safety and efficacy of perampanel in adv
Safety and efficacy of perampanel in advanced Parkinson's disease: A randomized, placebo-controlled study
✍ Karla Eggert; David Squillacote; Paolo Barone; Richard Dodel; Regina Katzenschla 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB 👁 1 views

Squillacote, received compensation from Eisai for their site's conduct of the study. Drs. Barone, Lees, and Oertel received honoraria from Eisai as members of the Advisory Board of this study. Dr. Rascol has received unrestricted scientific grant and honoraria from Eisai for his advice to the compan

A pilot evaluation of the tolerability,
A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients
✍ Robert A. Hauser; Eric Molho; Heidi Shale; Simon Pedder; Ernest E. Dorflinger 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 489 KB

## Abstract Tolcapone is a potent, reversible catechol‐O‐methyltransferase (COMT) inhibitor with both peripheral and central activity. It has been demonstrated to improve motor function and allow levodopa dose reductions in Parkinson's disease (PD) patients who are experiencing either a stable resp

Rivastigmine versus placebo in hyperhomo
Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients
✍ Paolo Barone; David J. Burn; Teus van Laar; Chuanchieh Hsu; Werner Poewe; Roger 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB

## Abstract The effects of rivastigmine versus placebo in Parkinson's disease dementia (PDD) patients with elevated or normal/low plasma homocysteine were determined. In this prospective analysis of a 24‐week, randomly assigned, placebo‐controlled study of rivastigmine in PDD, subpopulations compri